A meta-analysis of data from more than 160,000 diabetics has offered some convincing data to support the theory that PPARγ activation by glitazones--either Avandia (GlaxoSmithKline's rosiglitazone) or pioglitazone--offers significant protection against Parkinson's disease. And the researchers who did the study say that their work should help accelerate work in the field.
Following up on what's billed as the largest epidemiological study ever done on Parkinson's disease, a group of scientists at Aarhus University in Denmark say they have determined that the neurological ailment begins in the gut and then spreads through the body by way of the vagus nerve.
Acorda Therapeutics moved a step closer to collecting the payoff from its $525 million acquisition of Civitas, maker of an inhaled levodopa, in the scramble to deliver an improved formulation of the standard Parkinson's med. The conventional oral formulation suffers from unpredictable absorption in the bloodstream and a wearing-off effect after about 5 years.
The FDA lifted the clinical hold on Neuroderm's subcutaneously delivered Parkinson's candidates, paving the way for more studies of the liquid formulations of levodopa and carbidopa in the second half of this year. In response to the Friday morning news, the company's stock ended the day up more than 10%.
Getting drugs into the brain is one of the biggest challenges in medical research. Now a group of investigators at the University of North Carolina in Chapel Hill say they found an ideal method, hijacking tiny "bubbles" produced by cells and turning them into a delivery vehicle for a potent Parkinson's medication.
Exosomes are the small fat and protein bubbles that cells create to manage waste and transport materials. Naturally, then, the vesicles are ideal for use in drug delivery, and researchers are using exosomes to deliver antioxidants to the brain--bypassing the challenging blood-brain barrier--to treat Parkinson's disease.
Levodopa is often the drug of choice to mitigate the symptoms of Parkinson's disease, but getting the treatment into the bloodstream can be challenging because of the erratic muscle movement in Parkinson's patients' digestion systems. AbbVie's gel-based Duopa is designed to improve absorption of levodopa in the small intestine, and researchers at the University of Kentucky recently demonstrated long-term safety and efficacy of the delivery method.
A team of investigators at the Florida branch of Scripps Research Institute says that a little-understood enzyme known as serum glucocorticoid kinase 1 could play a role in preventing or treating Parkinson's disease.
The FDA wants to know how price comparisons in advertising affect people's perceptions of drug quality. The agency's Office of Prescription Drug Promotion is planning a new study to assess how diabetes patients and their doctors react to direct-to-consumer advertisements that feature price info.
The FDA just approved AbbVie's novel formulation of the standard Parkinson's drugs carbidopa and levodopa, Duopa, which is delivered straight into the patient's small intestine over 16 consecutive hours using an infusion pump and procedurally placed tube.